Skip to NavigationSkip to content

Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong

Published on 04/04/19 at 10:15am
Image Credit: NHS Confederation

Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA Times.  

The legal action comes after Sorrento accused Soon-Shiong of “catching and killing” a generic version of a cancer drug, which would have acted as competition to one owned by Celgene, a company in which he was the largest shareholder.

Sorrento claim Soon-Shiong acquired Cynviloq, a generic version of Celgene’s Abraxane, with the intention of stopping its progression to market.

The claims come after Sorrento sold Cynviloq to Soon-Shiong’s NantPharma, for $1.3 billion in 2015. However Sorernto are demanding $1 billion in damages as well as punitive damages, over allegations of fraud and breach of contract.

The lawsuit accuses Soon-Shiong of executing “the catching and killing of a cancer drug that — had it been brought to market as planned — would have saved patients, hospitals, and the United States government in excess of $1bn.”

Sorrento said it had agreed to work with Soon-Shiong in “good faith” in seeking to make Cynviloq a success.

“As alleged in the complaint, in addition to Sorrento, these actions have harmed patients, healthcare providers and payers, who have been deprived of Cynviloq — a potential treatment alternative that we believe would have been as safe, as efficacious and more affordable than Celgene’s blockbuster cancer drug, Abraxane,” the company said in a statement.

The firm also alleges Soon-Shiong took $90 million from Sorrento and Soon-Shiong joint venture Nantibody. Shares in Sorrento jumped 15% on announcement of the news.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches